Clinical Trial Update: AR101 Real-World Open-Label Extension Study [Phase 3]

View source ↗

Summary

Open-label extension of AR101 in peanut allergy completed; results posted in 2021. It provides long-term safety and tolerability data from a Phase 3 program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• AR101 (peanut oral immunotherapy)

Snippet

Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2021-11-02